30 results on '"Rosqvist, Kristina"'
Search Results
2. Care of Late‐Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries
- Author
-
Kruse, Christopher, primary, Lipinski, Anna, additional, Verheyen, Malte, additional, Balzer‐Geldsetzer, Monika, additional, Wittenberg, Michael, additional, Lorenzl, Stefan, additional, Richinger, Carmen, additional, Schmotz, Christian, additional, Tönges, Lars, additional, Woitalla, Dirk, additional, Klebe, Stephan, additional, Bloem, Bastiaan R., additional, Hommel, Adrianus, additional, Meissner, Wassilios G., additional, Laurens, Brice, additional, Boraud, Thomas, additional, Foubert‐Samier, Alexandra, additional, Vergnet, Sylvain, additional, Tison, François, additional, Costa, Nadège, additional, Odin, Per, additional, Rosqvist, Kristina, additional, Norlin, Jenny M., additional, Hjalte, Frida, additional, Schrag, Anette, additional, and Dodel, Richard, additional
- Published
- 2024
- Full Text
- View/download PDF
3. The late stage of Parkinson's –results of a large multinational study on motor and non-motor complications
- Author
-
Ferreira, Joaquim, Fabbri, Margherita, Tison, François, Foubert-Samier, Alexandra, Read, Joy, Meinders, Marjan, Koopmans, Raymond, Richinger, Carmen, Rosqvist, Kristina, Wittenberg, Michael, Neuser, Petra, Schrag, A., Hommel, A.L.A.J., Lorenzl, S., Meissner, W.G., Odin, P., Coelho, M., Bloem, B.R., and Dodel, R.
- Published
- 2020
- Full Text
- View/download PDF
4. A systematic practice review: Providing palliative care for people with Parkinson’s disease and their caregivers
- Author
-
Garon, Michela, primary, Weck, Christiane, additional, Rosqvist, Kristina, additional, Odin, Per, additional, Schrag, Anette, additional, Krikmann, Ülle, additional, Pedrosa, David J, additional, Antonini, Angelo, additional, Lorenzl, Stefan, additional, Martins Pereira, Sandra, additional, and Paal, Piret, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
- Author
-
Staubo, Sara C., primary, Fuskevåg, Ole Martin, additional, Toft, Mathias, additional, Lie, Ingeborg H., additional, Alvik, Kirsti M. J., additional, Jostad, Pål, additional, Tingvoll, Stein H., additional, Lilleng, Hallvard, additional, Rosqvist, Kristina, additional, Størset, Elisabet, additional, Odin, Per, additional, Dietrichs, Espen, additional, and Dietrichs, Erik Sveberg, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson's Disease Patients.
- Author
-
Janz, Carin, Timpka, Jonathan, Rosqvist, Kristina, Paul, Gesine, Storch, Alexander, and Odin, Per
- Subjects
PARKINSON'S disease ,PATIENT compliance ,HYPERSOMNIA ,EPWORTH Sleepiness Scale ,SYMPTOMS ,MOVEMENT disorders - Abstract
Background: Non-motor symptoms (NMS) reduce quality of life in Parkinson's disease (PD) patients, who experience three times more NMS than individuals without PD. While there are international and national NMS treatment guidelines, their implication in clinical practice remains unclear. Objective: This study aimed to investigate the adherence to pharmacological NMS treatment guidelines in patients with mild to moderately severe PD. Methods: 220 PD patients with ≥1 NMS based on the Non-Motor Symptom Questionnaire and a Hoehn and Yahr stage ≤4 were randomly selected from the Swedish Parkinson registry and screened for inclusion. NMS were evaluated using the International Parkinson and Movement Disorder Society–Non-Motor Rating Scale (MDS-NMS), Parkinson's Disease Sleep Scale 2, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Treatment was compared with Swedish national guidelines and international guidelines from the MDS Evidence-Based Medicine Committee. Results: Among 165 included patients, the median number of NMS was 14, and in median 7 symptoms were estimated to require treatment. The most common NMS requiring treatment were pain (69%) and urinary problems (56%). Treatment of depression and constipation demonstrated the highest adherence to guidelines (79% and 77%), while dysphagia and excessive daytime sleepiness exhibited the lowest adherence (0% and 4%). On average, only 32% of NMS were treated in accordance with guidelines. Conclusions: Adherence to pharmacological guidelines for NMS in patients with mild to severe PD was low. This study highlights the need for improved evaluation and treatment of NMS to enhance symptom management and quality of life among PD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
- Author
-
Staubo, Sara C., Fuskevåg, Ole Martin, Toft, Mathias, Lie, Ingeborg H., Alvik, Kirsti M. J., Jostad, Pål, Tingvoll, Stein H., Lilleng, Hallvard, Rosqvist, Kristina, Størset, Elisabet, Odin, Per, Dietrichs, Espen, and Dietrichs, Erik Sveberg
- Subjects
IMPULSE control disorders ,PARKINSON'S disease ,DOPAMINE agonists ,DRUG monitoring ,COMPULSIVE shopping - Abstract
Background and purpose: Impulse control disorders (ICDs) are common among Parkinson's disease patients using dopamine agonists. We wanted to determine whether ICD patients have higher dopamine agonist serum concentrations than those without any sign of ICD. Methods: Patients who used either pramipexole or ropinirole depot once daily were screened for ICDs using the validated Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease–Rating Scale. Those who scored above the cut‐off for one or more of the four defined ICDs (gambling, compulsive sexual behavior, compulsive shopping, and binge‐eating) were compared in a case–control study to patients who scored zero points (no evidence of ICD) on the same items. They were examined clinically and evaluated using relevant scales. Three blood samples were taken on the same day: before daily dose, and then 6 and 12 h later. Results: Forty‐six patients were included: 19 ICD‐positive and 27 controls. Ropinirole serum concentrations 6 h after daily intake (Cmax) were higher in the case group compared to the control group, as was the daily ropinirole dosage. No differences were observed in serum concentrations, dosage or total drug exposure for pramipexole. Disease duration and length of dopamine agonist treatment was significantly longer among ICD patients for ropinirole, but not for pramipexole. Conclusions: The use of pramipexole may in itself confer high ICD risk, whereas ICDs among ropinirole users depend more on serum concentration and drug exposure. The pharmacokinetic properties of ropinirole make it challenging to predict its effects on patients, which supports the need for therapeutic drug monitoring to reduce risk of ICD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary and Odin, Per, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Disease stage dependency of motor and non-motor fluctuations in Parkinson’s disease
- Author
-
Storch, Alexander, Rosqvist, Kristina, Ebersbach, Georg, NoMoFlu-PD Study Group, and Odin, Per
- Published
- 2019
- Full Text
- View/download PDF
10. A systematic practice review: Providing palliative care for people with Parkinson's disease and their caregivers.
- Author
-
Garon, Michela, Weck, Christiane, Rosqvist, Kristina, Odin, Per, Schrag, Anette, Krikmann, Ülle, Pedrosa, David J, Antonini, Angelo, Lorenzl, Stefan, Martins Pereira, Sandra, and Paal, Piret
- Subjects
PARKINSON'S disease diagnosis ,CONSENSUS (Social sciences) ,CINAHL database ,MEDICAL databases ,CAREGIVERS ,SOCIAL support ,MEDICAL information storage & retrieval systems ,HEALTH services accessibility ,SYSTEMATIC reviews ,MOVEMENT disorders ,INDIVIDUALITY ,CONTINUUM of care ,ADVANCE directives (Medical care) ,RESEARCH funding ,HEALTH care teams ,QUALITY of life ,DESCRIPTIVE statistics ,MEDLINE ,EMPIRICAL research ,PATIENT care ,PALLIATIVE treatment ,MENTAL health services ,NEURODEGENERATION ,SPIRITUAL care (Medical care) ,SYMPTOM burden - Abstract
Background: People with Parkinson's disease has significant and increasing physical, psychosocial and spiritual needs, as well as problems with coordination and continuity of care. Despite the benefits that palliative care could offer, there is no consensus on how it should be delivered. Aim: The aim of this study is to provide a pragmatic overview of the evidence to make clinical recommendations to improve palliative care for people with Parkinson's disease and their caregivers. Design: A systematic review method was adopted to determine the strength of evidence, supported by feedback from an expert panel, to generate the 'do', 'do not do' and 'do not know' recommendations for palliative care. Data sources: Searches were conducted via OVID to access CINAHL, MEDLINE, EMBASE and the Cochrane Library from 01/01/2006 to 31/05/2021. An additional search was conducted in December 2022. The search was limited to articles that included empirical studies of approaches to enabling palliative care. Results: A total of 62 studies met inclusion criteria. There is evidence that education about palliative care and movement disorders is essential. palliative care should be multi-disciplinary, individualised and coordinated. Proactive involvement and support of caregivers throughout the illness is recommended. Limited data provide referral indicators for palliative care integration. Discussions about advance care planning should be held early. Conclusions: Consideration of palliative care integration based on symptom burden and personal preferences, coordination and continuity of care are needed to maintain the quality of life of people with Parkinson's disease and their caregivers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study
- Author
-
M. Norlin, Jenny, Hjalte, Frida, Kruse, Christopher, Dodel, Richard, Rosqvist, Kristina, Odin, Per, and Norlin, Jenny
- Subjects
Sweden ,Neurology ,Quality of Life ,Medizin ,Humans ,Parkinson Disease ,Neurology (clinical) ,General Medicine ,Mental Status and Dementia Tests ,Delivery of Health Care - Abstract
Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results: In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion: Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.
- Published
- 2022
12. Chapter Five - Emergencies in pump therapies
- Author
-
Rosqvist, Kristina and Odin, Per
- Published
- 2023
- Full Text
- View/download PDF
13. Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study
- Author
-
Norlin, Jenny, primary, Hjalte, Frida, additional, Kruse, Christopher, additional, Dodel, Richard, additional, Rosqvist, Kristina, additional, and Odin, Per, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, Schrag, Anette, and Odin, Per
- Subjects
caregiver burden ,late stage ,informal caregiver ,Parkinson’s disease ,humanities ,Article - Abstract
Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease involving both motor and non-motor symptoms (NMS). In the late stage of the disease, Hoehn and Yahr (HY) stages IV-V, the symptomatology is often severe and patients become increasingly dependent on help in their daily life, resulting in an increased burden for the informal caregivers. To assess the implications of the caregiver burden, caregiver quality of life (QoL) was assessed in 74 informal caregivers to patients in late stage PD, by the Alzheimer’s Patient Partners Life Impact Questionnaire (APPLIQue), which has been found useful also in PD. The majority of caregivers were the spouse/partner. Individual items provided information on which aspects of caregiver burden were the most common, i.e., items: “feel guilty if not there” (71% affirmed), “situation wears me down” (65% affirmed) and “always on my mind” (61% affirmed). In simple linear regression analyses, female patient gender (p = 0.007), better cognition (p = 0.004), lower NMS burden (p = 0.012) and not being the partner (p = 0.022) were associated with better caregiver QoL. Multivariable linear regression analyses identified better cognition (p = 0.004) and female patient gender (p = 0.035) as independently associated with better informal caregiver QoL. Identifying and treating NMS as well as recognizing and alleviating caregiver burden seem essential to enhance QoL for both patients and caregivers in late stage PD.
- Published
- 2022
15. Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers—Study Protocol for a Multicentre, Randomized Controlled Trial
- Author
-
Meinders, Marjan J., primary, Gentile, Giovanni, additional, Schrag, Anette E., additional, Konitsiotis, Spiros, additional, Eggers, Carsten, additional, Taba, Pille, additional, Lorenzl, Stefan, additional, Odin, Per, additional, Rosqvist, Kristina, additional, Chaudhuri, K. Ray, additional, Antonini, Angelo, additional, Bloem, Bastiaan R., additional, and Groot, Marieke M., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Perspectives on Care for Late-Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary, Kylberg, Marianne, additional, Löfqvist, Charlotte, additional, Schrag, Anette, additional, Odin, Per, additional, and Iwarsson, Susanne, additional
- Published
- 2021
- Full Text
- View/download PDF
17. The late stage of Parkinson's –results of a large multinational study on motor and non-motor complications
- Author
-
Schrag, A., primary, Hommel, A.L.A.J., additional, Lorenzl, S., additional, Meissner, W.G., additional, Odin, P., additional, Coelho, M., additional, Bloem, B.R., additional, Dodel, R., additional, Ferreira, Joaquim, additional, Fabbri, Margherita, additional, Tison, François, additional, Foubert-Samier, Alexandra, additional, Read, Joy, additional, Meinders, Marjan, additional, Koopmans, Raymond, additional, Richinger, Carmen, additional, Rosqvist, Kristina, additional, Wittenberg, Michael, additional, and Neuser, Petra, additional
- Published
- 2020
- Full Text
- View/download PDF
18. Satisfaction with care in late stage Parkinson’s disease
- Author
-
Rosqvist, Kristina, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria H, Odin, Per, Rosqvist, Kristina, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria H, and Odin, Per
- Abstract
In late stage Parkinson’s disease (PD) (i.e., Hoehn and Yahr (HY) stages IV-V), both motor and nonmotor symptoms (NMS) are pronounced, and the patients become increasingly dependent on help in their daily life. Consequently, there is an increasing demand on health-care and social care resources for these patients and support for their informal caregivers. The aim of this study was to assess satisfaction with care in late stage PD patients and to identify factors associated with satisfaction with care. Moreover, to assess their informal caregivers’ satisfaction with support and to identify factors associated with caregivers’ satisfaction with support. Factors potentially associated with satisfaction with care/support were assessed in 107 late stage PD patients and their informal caregivers () and entered into multivariable logistic regression analyses. Fifty-eight (59%) of the patients and 45 (59%) of the informal caregivers reported satisfaction with their overall care/support. Patients satisfied with their care reported higher independence in activities of daily living (ADL) (Katz ADL index; ), less depressive symptoms (Geriatric Depression Scale, GDS-30; ), and higher individual quality of life (QoL) (Schedule for the Evaluation of Individual Quality of Life Questionnaire, SEIQoL-Q; ). Multivariable logistic regression analyses identified depressive symptoms () and independence in ADL () as independently associated with satisfaction with care. For informal caregivers, the analyses identified patients’ HY stage () and caregivers’ QoL (Alzheimer’s Carers Quality of Life Inventory, ACQLI; ) as independently associated with satisfaction with caregiver support. The results indicate that an effective both pharmacological and nonpharmacological PD therapy is important, to adequately treat motor and NMS (e.g., depressive symptoms) in order to improve depressive symptoms and patient independence in ADL. This may benefit not only the patients, but also their informal caregi
- Published
- 2019
- Full Text
- View/download PDF
19. Factors Associated with Health‐Related Quality of Life in Late‐Stage Parkinson's Disease.
- Author
-
Rosqvist, Kristina, Odin, Per, Lorenzl, Stefan, Meissner, Wassilios G., Bloem, Bastiaan R., Ferreira, Joaquim J., Dodel, Richard, and Schrag, Anette
- Subjects
- *
PARKINSON'S disease , *QUALITY of life , *OCCUPATIONAL therapists , *MEDICAL care , *ACTIVITIES of daily living , *NON-communicable diseases - Abstract
Background: There is limited knowledge on health‐related quality of life (HRQoL) in late‐stage Parkinson's disease (PD). Objective: To assess factors associated with HRQoL in patients with late‐stage PD, with a focus on health care provision. Methods: The Care of Late Stage Parkinsonism (CLaSP) project is the largest study on late‐stage PD to date. The current study analyzed data of 401 patients from 6 European countries in whom HRQoL was assessed with the 8‐item PD Questionnaire in patients without dementia. Factors potentially associated with HRQoL were assessed and examined in linear regression analyses. Results: Better HRQoL was associated with living at home, greater independence in activities of daily living (Schwab and England Scale), less severe disease (Hoehn and Yahr stage), better motor function (Unified PD Rating Scale Part III), and lower non‐motor symptoms burden (Non‐Motor Symptoms Scale [NMSS]) across all NMSS domains. Having a PDspecialist as physician for PD, contact with a PDnurse, and no hospital admission during the past 3 months were associated with better HRQoL, but having seen a physiotherapist or occupational therapist was associated with worse HRQoL. Conclusions: The results emphasize the importance of optimizing treatment for motor and multiple non‐motor symptoms to improve HRQoL in patients with late‐stage PD. PD‐specific health care resources, particularly PDnurses, are likely important in addressing issues to improve HRQoL in this population. Worse HRQoL in those who had recently seen a physiotherapist or occupational therapist may reflect referral based on factors not measured in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Satisfaction with Care in Late Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary, Hagell, Peter, additional, Iwarsson, Susanne, additional, Nilsson, Maria H, additional, and Odin, Per, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary, Odin, Per, additional, Hagell, Peter, additional, Iwarsson, Susanne, additional, Nilsson, Maria H., additional, and Storch, Alexander, additional
- Published
- 2019
- Full Text
- View/download PDF
22. Dopaminergic effect on non-motor symptoms in late stage Parkinson's disease
- Author
-
Rosqvist, Kristina, Odin, Per, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria, Storch, Alexander, Rosqvist, Kristina, Odin, Per, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria, and Storch, Alexander
- Abstract
BACKGROUND: Non-motor symptoms (NMS) are common in late stage Parkinson's disease (PD), as the frequency and severity of most of these symptoms increase with advancing disease. OBJECTIVE: To assess effect of dopaminergic therapy on NMS in late stage PD and to investigate relationships between dopaminergic effect on NMS and on motor function. METHOD: Thirty PD patients in Hoehn and Yahr (HY) stages IV and V in "on" were included. Dopaminergic effect on non-motor symptomatology was assessed by the modified version of the Non-Motor Symptoms Scale (NMSS) in the "off" and the "on" state during a standardized L-dopa test, in parallel also assessing motor function. RESULTS: NMS were common and many of the symptoms occurred in >80% of the individuals. The highest NMSS scores were seen within the NMSS domains 3: mood/apathy and 7: urinary in both the "off" and the "on" state. There was a statistically significant (p < 0.001) improvement in the modified NMSS total score (median) from 79 in "off" to 64 in "on". There were statistically significant differences between the "off" and the "on" state for domains 2: sleep/fatigue, 3: mood/apathy, 5: attention/memory, 6: gastrointestinal and 7: urinary. The differences in the NMSS score between the "off" and the "on" state were in general larger for motor responders than for motor non-responders. In motor non-responders, differences of the NMSS score between the "off" and the "on" state were found for the total score, domain 3: mood/apathy and its item 11-flat moods. CONCLUSION: There is an effect of dopaminergic medication on NMS in late stage PD, to some extent also for those with a non-significant response on motor function during L-dopa test. It is therefore of importance to optimize dopaminergic therapy in order to give the most effective symptomatic treatment possible.
- Published
- 2018
- Full Text
- View/download PDF
23. Levodopa effect and motor function in late stage Parkinson's disease
- Author
-
Rosqvist, Kristina, Horne, Malcolm, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria H, Odin, Per, Rosqvist, Kristina, Horne, Malcolm, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria H, and Odin, Per
- Abstract
BACKGROUND: It is unclear to which degree Levodopa (L-dopa) remains effective also in the late stage of Parkinson's disease (PD) and to which degree motor fluctuations and dyskinesias remain a problem. OBJECTIVE: To assess responsiveness of motor symptomatology to L-dopa in a group of patients with late stage PD. Moreover, to investigate the extent to which motor fluctuations and dyskinesias occur. METHODS: Thirty PD patients in Hoehn and Yahr (HY) stages IV and V in "on" were included. L-dopa responsiveness was assessed with a standardized L-dopa test in the defined "off" and defined "on" states. Motor function was assessed by the Unified PD Rating Scale (UPDRS) III and timed tests. Motor fluctuations and dyskinesias were assessed by the UPDRS IV. The participants were further monitored for 10 days with a mobile movement-analyses-system, the Parkinson's Kinetigraph (PKG). The median (q1-q3) L-dopa equivalent daily dose (LEDD) was 799 (536-973) mg. RESULTS: The UPDRS III score improved with ≥15% in 15 (50%) and with ≥30% in six (20%) participants during the L-dopa test. The median (q1-q3) UPDRS III score in "off" was 46 (37-53) and in "on" 36 (28-46). Twenty-one (70%) of the participants reported either predictable or unpredictable "off" fluctuations (items 36-37). The prevalence of dyskinesias (item 32, duration of dyskinesias ≥1) was 47%. The PKG indicated that dyskinesias primarily were mild and that a majority had a pronounced "off" symptomatology, spending a large proportion of the day either asleep or very inactive. CONCLUSIONS: Half of a group of patients with late stage PD had an L-dopa response of ≥15% on the UPDRS III. According to the UPDRS IV, a majority of the patients had motor fluctuations and about half had dyskinesias, although the PKG results suggested that these were not very severe.
- Published
- 2018
- Full Text
- View/download PDF
24. Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial.
- Author
-
Hommel, Adrianus L.A.J., Meinders, Marjan J., Weerkamp, Nico J., Richinger, Carmen, Schmotz, Christian, Lorenzl, Stefan, Dodel, Richard, Coelho, Miguel, Ferreira, Joaquim J., Tison, Francois, Boraud, Thomas, Meissner, Wassilios G., Rosqvist, Kristina, Timpka, Jonathan, Odin, Per, Wittenberg, Michael, Bloem, Bas R., Koopmans, Raymond T., and Schragand, Anette
- Subjects
PARKINSONIAN disorders ,PARKINSON'S disease ,MOVEMENT disorders ,ACTIVITIES of daily living ,SYMPTOMS - Abstract
Background: Treatment of patients with late-stage parkinsonism is often sub-optimal. Objective: To test the effectiveness of recommendations by a movement disorder specialist with expertise in late-stage parkinsonism. Methods: Ninety-one patients with late-stage parkinsonism considered undertreated were included in apragmatic a pragmatic multi-center randomized-controlled trial with six-month follow-up. The intervention group received a letter with treatment recommendations to their primary clinician based on an extensive clinical assessment. Controls received care as usual. The primary outcome was the Unified Parkinson Disease Rating Scale (UPDRS)part-II (Activities of Daily Living). Other outcomes included quality-of-life (PDQ-8), mental health (UPDRS-I), motor function (UPDRS-III), treatment complications (UPDRS-IV), cognition (Mini-mental-state-examination), non-motor symptoms (Non-Motor-Symptoms-scale), health status (EQ-5D-5L) and levodopa-equivalent-daily-dose (LEDD). We also assessed adherence to recommendations. In addition to intention-to-treat analyses, a per-protocol analysis was conducted. Results: Sample size calculation required 288 patients, but only 91 patients could be included. Treating physicians followed recommendations fully in 16 (28%) and partially in 21 (36%) patients. The intention-to-treat analysis showed no difference in primary outcome (between-group difference = –1.2, p = 0.45), but there was greater improvement for PDQ-8 in the intervention group (between-group difference = –3.7, p = 0.02). The per-protocol analysis confirmed these findings, and showed less deterioration in UPDRS-part I, greater improvement on UPDRS-total score and greater increase in LEDD in the intervention group. Conclusions: The findings suggest that therapeutic gains may be reached even in this vulnerable group of patients with late-stage parkinsonism, but also emphasize that specialist recommendations need to be accompanied by better strategies to implement these to further improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. The Prevalence and Determinants of Neuropsychiatric Symptoms in Late‐Stage Parkinsonism.
- Author
-
Hommel, Adrianus L.A.J., Meinders, Marjan J., Lorenzl, Stefan, Dodel, Richard, Coelho, Miguel, Ferreira, Joaquim J., Laurens, Brice, Spampinato, Umberto, Meissner, Wassilios, Rosqvist, Kristina, Timpka, Jonathan, Odin, Per, Wittenberg, Michael, Bloem PhD, Bas R., Koopmans, Raymond T., and Schrag, Anette
- Subjects
APATHY ,PARKINSONIAN disorders ,PARKINSON'S disease ,COGNITION disorders ,SYMPTOMS ,DEMOGRAPHIC characteristics - Abstract
Background: Late‐stage parkinsonism and Parkinson's disease (PD) are insufficiently studied population. Although neuropsychiatric symptoms (eg, psychosis, depression, anxiety, behavioral problems) are frequently present, their prevalence and clinical predictors remain unknown. Objective: To determine the prevalence and predictors of neuropsychiatric symptoms in late‐stage PD. Methods: We conducted a multinational study of patients with PD with ≥7 years disease duration and either a Hoehn and Yahr stage ≥4 or a Schwab and England score ≤ 50% in the on stage. Neuropsychiatric symptoms were assessed through interviews with carers using the Neuropsychiatric Inventory, with a frequency × severity score ≥ 4, indicating clinically relevant symptoms. The determinants analyzed were demographic characteristics, medication, and motor and nonmotor symptoms. Univariate and multivariate logistic analyses were performed on predictors of clinically relevant neuropsychiatric symptoms. Results: A total of 625 patients were recruited in whom the Neuropsychiatric Inventory could be completed. In 92.2% (576/625) of the patients, at least 1 neuropsychiatric symptom was present, and 75.5% (472/625) had ≥1 clinically relevant symptom. The most common clinically relevant symptoms were apathy (n = 242; 38.9%), depression (n = 213; 34.5%), and anxiety (n = 148; 23.8%). The multivariate analysis revealed unique sets of predictors for each symptom, particularly the presence of other neuropsychiatric features, cognitive impairment, daytime sleepiness. Conclusion: Neuropsychiatric symptoms are common in late‐stage PD. The strongest predictors are the presence of other neuropsychiatric symptoms. Clinicians involved in the care for patients with late‐stage PD should be aware of these symptoms in this specific disease group and proactively explore other psychiatric comorbidities once a neuropsychiatric symptom is recognized. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary, Odin, Per, additional, Hagell, Peter, additional, Iwarsson, Susanne, additional, Nilsson, Maria H., additional, and Storch, Alexander, additional
- Published
- 2018
- Full Text
- View/download PDF
27. Levodopa Effect and Motor Function in Late Stage Parkinson’s Disease
- Author
-
Rosqvist, Kristina, primary, Horne, Malcolm, additional, Hagell, Peter, additional, Iwarsson, Susanne, additional, Nilsson, Maria H., additional, and Odin, Per, additional
- Published
- 2018
- Full Text
- View/download PDF
28. Factors associated with life satisfaction in Parkinson's disease
- Author
-
Rosqvist, Kristina, Hagell, Peter, Odin, P., Ekström, H., Iwarsson, S., Nilsson, M. H., Rosqvist, Kristina, Hagell, Peter, Odin, P., Ekström, H., Iwarsson, S., and Nilsson, M. H.
- Abstract
OBJECTIVES: To identify factors associated with life satisfaction (LS) in people with Parkinson's disease (PD), including a specific focus on those with late-stage PD. MATERIAL AND METHODS: The study included 251 persons with PD (median age 70 years; PD duration 8 years). Analyses involved the total sample and a subsample with late-stage PD, that is Hoehn and Yahr stages IV and V (n=62). LS was assessed with item 1 of the Life Satisfaction Questionnaire (LiSat-11). Simple logistic regression analyses were performed for both the total sample and for the subsample with late-stage PD. For the total sample, a multivariable logistic regression analysis was also performed. RESULTS: In the total sample, 12 of the 20 independent variables were significantly associated with LS: need of help with ADL; walking difficulties; number of non-motor symptoms (NMS); fatigue; depressive symptoms; general self-efficacy; motor symptoms; pain; PD severity; freezing episodes; gender (woman); and fluctuations. When controlling for age and gender in the multivariable logistic regression model, depressive symptoms were negatively associated with high LS and general self-efficacy was positively associated with high LS. In late-stage PD, simple logistic regression analyses (controlling for age and gender) identified the following factors as associated with LS: number of NMS, general self-efficacy, walking difficulties and fatigue. CONCLUSIONS: This study provides new knowledge on factors associated with LS in a PD sample, including those with late-stage PD. As the ultimate goal for PD care should be improvement in LS, the results have direct clinical implication.
- Published
- 2017
- Full Text
- View/download PDF
29. Levodopa effect and motor function in late stage Parkinson’s disease
- Author
-
Rosqvist, Kristina, Horne, Malcolm, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria, Odin, Per, Rosqvist, Kristina, Horne, Malcolm, Hagell, Peter, Iwarsson, Susanne, Nilsson, Maria, and Odin, Per
- Abstract
Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or whether motor fluctuations and dyskinesias are present. Background: A majority of PD patients treated with L-dopa develop motor complications, in many cases within a few years of treatment. It is unclear to which degree L-dopa remains effective also in the last stages and whether motor fluctuations and dyskinesias remain a problem. Methods: The study included 30 patients with PD in Hoehn and Yahr (HY) stages IV and V in “on” and/or having a substantial need of help with ADL (<50% Schwab and England Scale) and having been diagnosed with PD for =7 years. Nineteen were men, median age 83 and median PD duration 12 years. Nineteen were in HY stage IV and 11 in V. L-dopa responsiveness was assessed with an L-dopa test and motor evaluation according to a standardized protocol in the defined “off” and defined “on” state. Motor performance was assessed by the Unified PD Rating Scale (UPDRS) III and timed tests for gait and hand-arm. The participants were further evaluated with a mobile movement-analyses-system, the Parkinson’s Kinetigraph (PKG) for 10 days. Results: The number of participants with an improvement in UPDRS III during L-dopa test of =15% were 15 (50%) and of =30% were 6 (20%). The median UPDRS III score in “off” was 46 (q1-q3, 37-53) and in “on” 36 (28-46), with a median improvement of 15.5% (8-27%), p<0.001. There was a statistically significant effect in almost all variables; UPDRS III total score; speech (item 18); resting tremor (item 20); tremor (items 20, 21); rigidity (item 22); bradykinesia (items 23-26, 31); gait (item 29); axial signs (items 18, 19, 22, 27-30); dyskinesias (Clinical Dyskinesia Rating Scale); hand-arm movement; gait test and blood pressure. According to the UPDRS IV, 67% experienced predictable off-fluctuations, while 30% had unpredictable off-fluctuations. The p
- Published
- 2017
30. Life satisfaction in Parkinson’s disease : associated factors
- Author
-
Rosqvist, Kristina, Hagell, Peter, Odin, Per, Iwarsson, Susanne, Ekström, Henrik, Nilsson, Maria, Rosqvist, Kristina, Hagell, Peter, Odin, Per, Iwarsson, Susanne, Ekström, Henrik, and Nilsson, Maria
- Abstract
Objective: To identify factors associated with life satisfaction (LS) in people with Parkinson’s disease (PD), including a specific focus on those with late stage PD. Background: Despite that patients with PD have an increased risk of reduced LS, there is limited knowledge regarding which factors are associated with LS. Such knowledge could serve as an important base for optimizing treatment and care. Concerning patients with late stage PD, i e Hoehn and Yahr (HY) IV-V, no published study has specifically addressed LS for this group. Methods: Data from 251 persons with PD (median age 70 years and duration 8 years) was analyzed statistically; the total sample was assessed and a subsample with late stage PD was further evaluated separately. LS was assessed by item 1 of the Life Satisfaction Questionnaire (LiSat-11). A large number of independent variables were described in relation to HY for groups HY I-III and IV-V, differences between the groups were tested. Sample characteristics in relation to LS were tested with simple logistic regression analyses. Independent variables with a p-value < 0.3 in the simple logistic regressions were entered into a multiple logistic regression model. For the subsample with late stage PD, simple logistic regression analyses were calculated. Results: The simple logistic regression analyses showed that 11 out of the 20 independent variables were significantly associated with LS: need of help with ADL; walking difficulties; number of non-motor symptoms (NMS); fatigue; depressive symptoms; general self-efficacy; pain; PD severity; freezing episodes; gender (women) and fluctuations. When controlling for age and gender in the multiple logistic regression model, two independent variables were found to be independently associated with LS; depressive symptoms (negatively associated with high LS) and general self-efficacy (positively associated with high LS). For late stage PD, when controlling for age and gender in simple logistic regressio
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.